Orphan Drug Designations as Valuable Intangible Assets for IPO Investors in Pharma-Biotech Companies

Philippe Gorry and Diego Useche

A chapter in Economic Dimensions of Personalized and Precision Medicine, 2018, pp 305-334 from National Bureau of Economic Research, Inc

Date: 2018
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
http://www.nber.org/chapters/c13995.pdf (application/pdf)

Related works:
Working Paper: Orphan Drug Designations as Valuable Intangible Assets for IPO Investors in Pharma-Biotech Companies (2017)
Working Paper: Orphan Drug Designations as valuable Intangible assets for IPO Investors in Pharma-Biotech Companies (2016)
Working Paper: Orphan Drug Designations as Valuable intangible assets for Ipo Investors in Pharma-biotech companies (2015)
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nbr:nberch:13995

Ordering information: This item can be ordered from
http://www.nber.org/chapters/c13995

Access Statistics for this chapter

More chapters in NBER Chapters from National Bureau of Economic Research, Inc National Bureau of Economic Research, 1050 Massachusetts Avenue Cambridge, MA 02138, U.S.A.. Contact information at EDIRC.
Bibliographic data for series maintained by ().